You are here

• Home
• Drug Products
• All Drug Products

• A multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 2 trial to evaluate the efficacy and safety of dapagliflozin as monotherapy in Japanese subjects with type 2 diabetes mellitus who have inadequate glycemic

Disease

diabetes mellitus

Drug Name

dapagliflozin

Generic Name

dapagliflozin

Sponsor

AstraZeneca

Drug Status

Approved Medicine

Phase

II

Start Date

Aug 17, 2009

Study Name

D1692C00005

Study Id

D1692C00005

ClinicalTrials.gov ID

NCT00972244

Recruiting Status

Closed

Protocol Status

Not Available

Report

Oct 20, 2010

• D1692C00005.pdf (135 KB)

Page tools

• Print
• Bookmark this page